Lymphoma

Punctual and kinetic minimal residual disease analysis could be a robust predictor of mantle cell lymphoma’s natural history and could represent an adaptable model for continuous patient risk assessment.

Based on results from the phase 3 TRANSFORM trial, the FDA has approved lisocabtagene maraleucel for the second-line treatment of relapsed/refractory large B-cell lymphoma.

The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.

The 3-year follow-up update from the phase 2 ZUMA-2 trial showed continued responses for patients with relapsed/refractory mantle cell lymphoma treated with brexucabtagene autoleucel.

This review article written by Meghana Kesireddy, MBBS and Matthew A. Lunning, MD, reviews management and treatment of relapsed/refractory large B-cell lymphoma.

An expansion cohort from the phase 2 EPCORE NHL-1 trial demonstrated strong efficacy of epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

Based on results from the phase 1/2 GO29781 trial, the European Commission has approved mosunetuzumab for adult patients with relapsed/refractory follicular lymphoma.

Treatment with zanubrutinib and obinutuzumab improved outcomes in patients with relapsed/refractory follicular lymphoma vs obinutuzumab monotherapy.

Subgroup analysis of the RE-MIND trial support use of tafasitamab plus lenalidomide to treat high-risk diffuse large B-cell lymphoma.

The phase 2 PILOT study showed encouraging overall response rates with lisacabtagene maraleucel in the second-line or beyond setting among patients with relapsed/refractory large B-cell lymphoma who did not receive hematopoietic stem cell transplantation.

Epcoritamab plus rituximab and lenalidomide yielded a 100% response rate in patients with relapsed or refractory follicular lymphoma.

High response rates were noted in a phase 1/2 trial of the bispecific antibody epcoritamab to treat first-line, high-risk diffuse large B-cell lymphoma.

Phase 2 data indicate promising responses are possible with fixed-duration glofitamab in patients with heavily pretreated, highly refractory large B-cell lymphoma.

Prior findings showing the benefit of brentuximab vedotin plus chemotherapy vs chemotherapy alone for the treatment of patients with previously untreated stage III/IV classical Hodgkin lymphoma was supported by 6-year updated overall survival data.

Results of the GEMSTONE-201 study demonstrate complete responses were achieved in roughly one-third of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma who were treated with sugemalimab.

The combination of ibrutinib plus the chemotherapy bendamustine and rituximab immunotherapy elicited the highest PFS rate ever reported for this patient population, according to an expert.

Results from the phase 2 ELARA trial supported an accelerated approval from the FDA for tisagenlecleucel for patients with relapsed/refractory follicular lymphoma.

Treatment with brexucabtagene autoleucel appears to be a cost-effective treatment for patients with relapsed/refractory mantle cell lymphoma following treatment with a Bruton tyrosine kinase inhibitor.

Sunita D. Nasta, MD, gives her perspective on emerging treatments for peripheral T-cell lymphomas.

This review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.

Patients with relapsed/refractory B-cell non-Hodgkin lymphoma who experienced grade 3 or higher immune effector cell–associated neurotoxicity syndrome who were treated with early intrathecal therapy experienced improved survival.

Although treatment with polatuzumab vedotin (Polivy) after anti-CD19 CAR T-cell therapy was safe and effective for patients with relapsed/refractory large B-cell lymphoma, it had a short duration of response.

Despite its use in a population with broad characteristics and high-risk features, a real-world outcome analysis demonstrated brexucabtagene autoleucel’s feasibility and efficacy in those with mantle cell lymphoma.

Frederick Lock, MD, spoke about clinicians can best utilize the treatment of axicabtagene ciloleucel for patients with large B-cell lymphoma.

Investigators highlight key findings from an early cost analysis of phase 1/2 trials examining Burton tyrosine kinase inhibitors in patients with relapsed/refractory mantle cell lymphoma.

A comparison of axicabtagene ciloleucel and tisagenlecleucel for patients with follicular lymphoma yielded comparable outcomes.

Treatment with several CAR T-cell products resulted in notable responses without an increase in cytokine release syndrome or neurotoxicity in large B-cell lymphoma with central nervous system involvement.

The use of axicabtagene ciloleucel for relapse/refractory indolent non-Hodgkin lymphoma continued the duration of response during the follow-up of the phase 2 ZUMA-5 trial.

Patients with relapsed/refractory large B-cell lymphomas experienced durable responses to treatment with lisocabtagene maraleucel.

The long-term overall survival rate yielded by axicabtagene ciloleucel appeared to support 1- and 2-year event-free survival as a surrogate end point in relapsed/refractory large B-cell lymphoma.